Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

September 11, 2020

Study Completion Date

September 11, 2020

Conditions
SMA
Interventions
BIOLOGICAL

Onasemnogene Abeparvovec-xioi

Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).

Trial Locations (10)

Unknown

University Hospital Ghent Neuromuscular reference center, Ghent

Neuropédiatrie - Centre de Référence des Maladies Neuromusculaires, Liège

Hôpital Armand Trousseau, Paris

Istituto Gianninia Gaslini, Genova

"Policlinico G. Martino", Messina

Carlo Besta Neurological Research Institute, Milan

University of Milan, Milan

Policlinico Gemelli, Rome

Great Ormond Street Hospital for Children, London

The John Walton Muscular Dystrophy Research Centre MRC Centre for Neuromuscular Diseases at Newcastle, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Novartis Gene Therapies

INDUSTRY